CA-NETAPP
12.5.2020 20:23:04 CEST | Business Wire | Press release
NetApp (NASDAQ: NTAP), the leader in cloud data services, today announced the appointment of Cesar Cernuda as president of NetApp, reporting to CEO George Kurian, effective in July. He will lead our global go-to-market operations spanning sales, marketing, services, and support. Cernuda joins NetApp from Microsoft, where he was president of Microsoft Latin America and corporate vice president of Microsoft Corporation. He brings with him extensive experience in leading business transformation, building diverse, high-performing teams, and driving a successful cloud business. In his role as president, Cernuda will continue to evolve the NetApp® go-to-market strategy and organization to accelerate growth by transforming how we approach the changing customer landscape and capture new growth opportunities, particularly in cloud.
Today’s technologies and the rapid pace of digital innovation have created new opportunities for organizations to engage with and serve their customers. To capture these opportunities, NetApp’s marketing, sales, and services and support organizations will be combined under Cernuda to create an integrated, global go-to-market organization. Cernuda’s experience in leading global enterprise sales and transforming business will enable him to foster tighter alignment between the teams, helping NetApp to quickly capture new growth opportunities in enterprise storage systems and cloud data services.
“As we look to accelerate our cloud and software strategy, Cesar’s experience in successfully transforming large global organizations will strengthen NetApp’s position as a leader in cloud data services and drive value for our shareholders,” said George Kurian, chief executive officer. “I’m excited to welcome a leader of his caliber. I look forward to him bringing to the team his passion for strong results, his commitment to building diverse, high-performing teams, and his experience in business transformation as we continue to evolve our go-to-market strategy to reflect the changing customer landscape.”
“I believe that NetApp will become a key partner in every organization’s data strategy, and I am looking forward to being a part of it,” said Cernuda. “During the past years, the key hyperscale public cloud vendors have bet on NetApp technology to support them with their customer offerings, and I believe this is one of the best examples of how NetApp has been transforming to become a cloud-first organization. I am thrilled with the opportunity to help and support customers and partners across the globe manage and protect one of their most important assets—their data.”
About Cesar Cernuda
Before joining NetApp, Cernuda served as president of Microsoft Latin America and corporate vice president of Microsoft Corporation, where he was responsible for all of Microsoft’s products, services, and support offerings across Latin America, and for accelerating the company’s transformation for the mobile-first, cloud-first era.
Before that, Cernuda was president of Microsoft Asia Pacific, where he led the company’s commercial and consumer products and service and support offerings. He also served as the worldwide vice president of Microsoft Business Solutions sales and field operations. He oversaw the Microsoft ERP and CRM go-to-market business worldwide. Earlier, he was vice president of Microsoft Business Solutions International, where he was responsible for sales, presales, channel, marketing, product, support, and services.
Cernuda earned a bachelor’s degree in business administration and marketing from ESIC University in Spain and completed a management development program (PDD) from IESE Business School at the University of Navarra in Spain. In 2012, he completed the “Leadership for Senior Executives” program offered by Harvard Business School. Cernuda is an independent board member of GESTAMP, a multinational company that specializes in the design, development, and manufacture of highly engineered metal components for the automotive industry.
About NetApp
NetApp is the leader in cloud data services, empowering global organizations to change their world with data. Together with our partners, we are the only ones who can help you build your unique data fabric. Simplify hybrid multicloud and securely deliver the right data, services, and applications to the right people at the right time. Learn more at www.netapp.com .
NETAPP, the NETAPP logo, and the marks listed at http://www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200512005824/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom